Morgan Stanley Call 160 RVTY 20.1.../ DE000ME65S93 /
| 8/14/2024 10:57:58 AM | Chg.0.000 | Bid4:40:57 PM | Ask4:40:57 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.270EUR | 0.00% | 0.270 Bid Size: 40,000 |
0.380 Ask Size: 40,000 |
Revvity Inc | 160.00 USD | 12/20/2024 | Call |
GlobeNewswire
6/20
Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research
GlobeNewswire
6/3
Orion is developing the Finnish life science industry in a unique collaboration project
GlobeNewswire
5/28
Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Grea...
GlobeNewswire
5/9
Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific N...
GlobeNewswire
1/19
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Pan...
GlobeNewswire
1/8
Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend
GlobeNewswire
11/30/2023
Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD
GlobeNewswire
11/13/2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. -...
GlobeNewswire
11/5/2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. - ...
GlobeNewswire
5/18/2021
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in the UK COVID-19 Human Challenge Study...
GlobeNewswire
5/11/2021
Oxford Immunotec’s T-SPOT.COVID Test is Used in the COV-AD Clinical Study to Investigate the Immunol...
GlobeNewswire
4/29/2021
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell R...
